Dr Mohty on Extended Follow-up Data from MagnetisMM-3 With Elranatamab in R/R Myeloma


Mohamad Mohty, MD, PhD, discusses extended follow-up from cohort A of the phase 2 MagnetisMM-3 trial of elranatamab in patients with relapsed/refractory multiple myeloma.

Mohamad Mohty, MD, PhD, professor of Hematology and head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and Sorbonne University in Paris, France, discusses extended follow-up from cohort A of the phase 2 MagnetisMM-3 trial (NCT04649359) of elranatamab (PF-06863135) monotherapy in patients with relapsed/refractory multiple myeloma who received at least 1 proteasome inhibitor, 1 immunomodulatory drug, and 1 anti-CD38 antibody, and were naïve to BCMA-directed therapies.

Data presented at the 2023 EHA Congress showed that among all evaluable patients in cohort A (n = 123), elranatamab elicited an overall response rate (ORR) of 61.0% (95% CI, 51.8%-69.6%), including a stringent complete response (sCR) rate of 15.4%, a complete response (CR) rate of 19.5%, a very good partial response rate (VGPR) of 21.1%, and a partial response (PR) rate of 4.9%. In patients who received 2 or 3 prior lines of therapy (n = 26), the ORR was 73.1% with sCR, CR, VGPR, and PR rates of 19.2%, 26.9%, 23.1%, and 3.8%, respectively.

Additional data showed that the ORR and CR or better rate for patients without extramedullary disease (n = 84) were 71.4% and 40.5%, respectively. Those rates were 75.0% and 53.6%, respectively, for those with Revised International Staging System stage I disease (n = 28). 

The median time to response for the overall population was 1.2 months (range, 0.9-7.4). Among evaluable patients who achieved a sCR or CR (n = 29), the minimal residual disease–negativity rate at a 10-5 sensitivity was 89.7%. 

At a median follow-up of 14.7 months for the overall population in cohort A, the median progression-free survival (PFS) and overall survival (OS) had not yet been reached. The 15-month PFS and OS rates were 50.9% and 56.7%, respectively. The 15-month duration of response rate was 71.5%. The survival rates observed thus far are promising, if not unprecedented, for this patient population, Mohty concludes.

Related Videos
Expert on MM
Expert on MM
Naval G. Daver, MD
Pasi A. Jänne, MD, PhD
Saad Z. Usmani, MD, MBA, FACP
J. Randolph (Randy) Hecht, MD
Alessandro Di Federico, MD
Qian (Janie) Qin, MD
Judy C. Boughey, MD
Related Content